Prelude Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Prelude Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-69,038	Closed	-$5.2M	–	2171
2022 Q2	$5.2M	Buy	+69,038	New	+$3.07M	0.15%	99
2019 Q4	–	Sell	-11	Closed	–	–	2362
2019 Q3	$0	Buy	+11	New	+$479	﹤0.01%	2197

Prelude Capital Management's TPTX Position: Q3 2022 in Review

Prelude Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 69,038 shares — an estimated $5.2M sold.

Prelude Capital Management first reported a position in TPTX in Q3 2019 and held it in 2 quarters. The position peaked at $5.2M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Prelude Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Prelude Capital Management sold 69,038 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $5.2M.
Prelude Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
Prelude Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.2M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.